Meropenem Plasma Concentration Measurements at the Pediatric Medical Ward, Oslo University Hospital, Rikshospitalet
The object of the study is to investigate whether all included patients receive treatment that is effective against all bacteria that are defined as sensitive to meropenem with the current treatment regimen. Will the investigators findings motivate routine monitoring of plasma concentrations in children receiving meropenem? Up to 50 patients will be included in the study, and all participants are children.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Meropenem Plasma Concentration Measurements at the Pediatric Medical Ward, Oslo University Hospital, Rikshospitalet|
- We will determine how many of the patients in our material that have plasma concentrations of meropenem above 8 mg/l for at least 40% and 75% of the time. [ Time Frame: 1 dosing interval (8 hours) ] [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
Two blood samples are taken from each included patient. (Each 2 ml heparin full blood).
|Study Start Date:||January 2011|
|Study Completion Date:||January 2014|
|Primary Completion Date:||January 2014 (Final data collection date for primary outcome measure)|
Children receiving meropenem
Children aged from 3 months to 18 years that receive treatment with meropenem.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01289249
|Oslo univeristy hospital, Rikshospitalet|
|Oslo, Norway, 0424|
|Study Director:||Odd Brørs, Dr Med||Oslo University Hospital|
|Study Chair:||Margrete L Burns, BMed||Oslo univeristy hospital|
|Study Chair:||Øystein Riise, PhD||Oslo University Hospital|
|Study Chair:||Tore Abrahamsen, Dr Med||Oslo univeristy hospital|
|Study Chair:||Gaut Gadeholt, Dr Med||Oslo University Hospital|